Daniel, Bence http://orcid.org/0000-0002-2410-8767
Yost, Kathryn E.
Hsiung, Sunnie http://orcid.org/0000-0002-4813-7220
Sandor, Katalin http://orcid.org/0000-0003-2892-4865
Xia, Yu
Qi, Yanyan
Hiam-Galvez, Kamir J. http://orcid.org/0000-0002-1956-0257
Black, Mollie
J. Raposo, Colin http://orcid.org/0000-0002-5230-7931
Shi, Quanming
Meier, Stefanie L.
Belk, Julia A. http://orcid.org/0000-0003-4724-6158
Giles, Josephine R.
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Chang, Howard Y. http://orcid.org/0000-0002-9459-4393
Egawa, Takeshi http://orcid.org/0000-0001-7489-1051
Satpathy, Ansuman T. http://orcid.org/0000-0002-5167-537X
Funding for this research was provided by:
Foundation for the National Institutes of Health (K08CA230188)
Article History
Received: 16 December 2021
Accepted: 13 September 2022
First Online: 26 October 2022
Competing interests
: A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Allogene Therapeutics and Merck Research Laboratories. H.Y.C. is a cofounder of Accent Therapeutics, Boundless Bio and Cartography Biosciences and an advisor to 10x Genomics, Arsenal Biosciences and Spring Discovery. K.E.Y. is a consultant for Cartography Biosciences. J.A.B. is a consultant for Immunai. E.J.W. is an advisor for Danger Bio, Marengo, Janssen, NewLimit Inc., Pluto Immunotherapeutics, Related Sciences, Rubius Therapeutics, Synthekine and Surface Oncology. E.J.W. is a founder of Surface Oncology, Danger Bio, and Arsenal Biosciences. The remaining authors declare no competing interests.